Aktuellt
SENASTE
Redeye is positively surprised by the evaluation agreement with MSRD, a part of the Otsuka pharmaceutical family of companies, regarding the preclinical candidates IRL757 & IRL942. MSRD will exclusively evaluate and review the compounds in exchange for providing IRLAB with an upfront payment. We assume that the upfront payment probably is relatively small at this point (we will see in upcoming reports) but we like the early validation and the potential of an early licensing deal, which could extend the cash runway further, which would be valuable. We reiterate our base case for now and hope to learn more about the collaboration soon.
LÄS MER
